Mp10-17 Impact of Corticosteroid Administration on Treatment Effectiveness in Patients With Advanced Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitor-Based Combination Therapy

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP10)1 May 2024MP10-17 IMPACT OF CORTICOSTEROID ADMINISTRATION ON TREATMENT EFFECTIVENESS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH IMMUNE CHECKPOINT INHIBITOR-BASED COMBINATION THERAPY Maki Yoshino, Hiroki Ishihara, Chika Nagahisa, Yuki Nemoto, Ryo Ishiyama, Takeshi Ikeda, Yuki Kobari, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, and Toshio Takagi Maki YoshinoMaki Yoshino , Hiroki IshiharaHiroki Ishihara , Chika NagahisaChika Nagahisa , Yuki NemotoYuki Nemoto , Ryo IshiyamaRyo Ishiyama , Takeshi IkedaTakeshi Ikeda , Yuki KobariYuki Kobari , Hidekazu TachibanaHidekazu Tachibana , Hironori FukudaHironori Fukuda , Kazuhiko YoshidaKazuhiko Yoshida , Hiroaki ShimmuraHiroaki Shimmura , Yasunobu HashimotoYasunobu Hashimoto , Tsunenori KondoTsunenori Kondo , and Toshio TakagiToshio Takagi View All Author Informationhttps://doi.org/10.1097/01.JU.0001008588.39303.c9.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The impact of corticosteroid administration for immune-related adverse events (irAEs) on treatment effectiveness in patients with advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitor (ICI)-based combination therapy remains unclear. This study aimed to clarify the prognostic impact of corticosteroid administration on clinical outcomes in dual ICI combination therapy (i.e., immunotherapy [IO]-IO) and combinations of ICIs with tyrosine kinase inhibitors (TKIs) (i.e., IO-TKI) for RCC. METHODS: We retrospectively evaluated the clinical data of 194 patients who received the IO-IO or IO-TKI as first-line therapy. The patients were divided into two groups according to corticosteroid administration requirements within the initial three months of treatment. Between the two groups, overall survival (OS) and progression-free survival (PFS) were compared in each treatment group. RESULTS: Overall, 101 (52.0%) and 93 (48.0%) patients received the IO-IO and IO-TKI, respectively. Among them, 32 (31.7%) and 9 (9.7%) patients in the IO-IO and IO-TKI groups received corticosteroids within the initial three months, respectively. In the IO-IO group, OS was significantly longer in patients receiving early corticosteroids than those without (median: 77.6 vs. 44.2 months, p=0.0230), and PFS was not significantly different between the two groups (median: 10.2 vs. 6.1 months, p=0.1272) (Figure 1). Subsequent multivariable analysis showed that corticosteroid administration was an independent predictor of a longer OS (hazard ratio: 0.381, p=0.0329). In the IO-TKI group, both OS and PFS were not significantly different regarding corticosteroid administration (p=0.495, p=0.169) (Figure 2). CONCLUSIONS: The corticosteroid administration did not decline the treatment effectiveness of ICI-combination therapies for advanced RCC despite the regimens. Download PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e146 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Maki Yoshino More articles by this author Hiroki Ishihara More articles by this author Chika Nagahisa More articles by this author Yuki Nemoto More articles by this author Ryo Ishiyama More articles by this author Takeshi Ikeda More articles by this author Yuki Kobari More articles by this author Hidekazu Tachibana More articles by this author Hironori Fukuda More articles by this author Kazuhiko Yoshida More articles by this author Hiroaki Shimmura More articles by this author Yasunobu Hashimoto More articles by this author Tsunenori Kondo More articles by this author Toshio Takagi More articles by this author Expand All Advertisement PDF downloadLoading ...